NCT04839926View on ClinicalTrials.gov

A Single Ascending Dose Study Of CY150112 After Single Oral Administration in Healthy Chinese Subjects

PHASE1UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 2, 2021

Primary Completion Date

August 1, 2021

Study Completion Date

August 1, 2021

Conditions
Schizophrenia
Interventions
DRUG

0.5mg CY150112

single oral CY150112 while fasting on day 1.

DRUG

1.5mg CY150112

single oral CY150112 while fasting on day 1.

DRUG

4.5mg CY150112

single oral CY150112 while fasting on day 1.

DRUG

10mg CY150112

single oral CY150112 while fasting on day 1.

DRUG

18mg CY150112

single oral CY150112 while fasting on day 1.

DRUG

24mg CY150112

single oral CY150112 while fasting on day 1.

Trial Locations (1)

200030

RECRUITING

Shanghai Mental Health Center, Shanghai

Sponsors
All Listed Sponsors
lead

Jiangsu Nhwa Pharmaceutical Co., Ltd.

INDUSTRY

NCT04839926 - A Single Ascending Dose Study Of CY150112 After Single Oral Administration in Healthy Chinese Subjects | Biotech Hunter | Biotech Hunter